Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
40 hedge funds and large institutions have $29.1M invested in Viracta Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 18 closing their positions.
108% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $681K
24% more capital invested
Capital invested by funds: $23.5M → $29.1M (+$5.56M)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
29% less funds holding
Funds holding: 56 → 40 (-16)
89% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$220K |
| 2 |
Renaissance Technologies
New York
|
+$198K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$175K |
| 4 |
NFG
Noven Financial Group
Denver,
Colorado
|
+$138K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$73.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$314K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$290K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$232K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$133K |
VIRX Hedge Fund Activity: Q3 2016 in Review
40 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2016, worth a combined $29.1M — up 24% from $23.5M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VIRX and 2 opened new positions — a net loss of 16 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was Frontier Wealth Management, adding an estimated $220K. The largest seller was Great Point Partners, cutting an estimated $1.2M.
- 40 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2016, down from 56 in Q2 2016.
- Funds reported $29.1M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2016, up 24% quarter-over-quarter.
- 2 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2016 and 18 closed out, a net change of -16 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2016 was Frontier Wealth Management, an estimated $220K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2016 was Great Point Partners, an estimated $1.2M sold.
Based on aggregated 13F filings for Q3 2016.